Tutt, Andrew N. J., Garber, Judy E., Kaufman, Bella, Viale, Giuseppe, Fumagalli, Debora, Rastogi, Priya, Gelber, Richard D., de Azambuja, Evandro ORCID: 0000-0001-9501-4509, Fielding, Anitra, Balmana, Judith, Domchek, Susan M., Gelmon, Karen A., Hollingsworth, Simon J., Korde, Larissa A., Linderholm, Barbro, Bandos, Hanna, Senkus, E., Suga, Jennifer M., Shao, Z., Pippas, Andrew W., Nowecki, Zbigniew, Huzarski, Tomasz, Ganz, Patricia A., Lucas, Peter C., Baker, Nigel, Loibl, Sibylle, McConnell, Robin, Piccart, Martine, Schmutzler, Rita, Steger, Guenther G., Costantino, Joseph P., Arahmani, Amal, Wolmark, Norman, McFadden, Eleanor, Karantza, Vassiliki, Lakhani, Sunil R., Yothers, Greg ORCID: 0000-0002-7965-7333, Campbell, Christine and Geyer, Charles E. (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N. Engl. J. Med., 384 (25). S. 2394 - 2406. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Full text not available from this repository.

Abstract

BACKGROUND Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer. METHODS We conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly assigned (in a 1:1 ratio) to 1 year of oral olaparib or placebo. The primary end point was invasive disease-free survival. RESULTS A total of 1836 patients underwent randomization. At a prespecified event-driven interim analysis with a median follow-up of 2.5 years, the 3-year invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the placebo group (difference, 8.8 percentage points; 95% confidence interval [CI], 4.5 to 13.0; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41 to 0.82; P<0.001). The 3-year distant disease-free survival was 87.5% in the olaparib group and 80.4% in the placebo group (difference, 7.1 percentage points; 95% CI, 3.0 to 11.1; hazard ratio for distant disease or death, 0.57; 99.5% CI, 0.39 to 0.83; P<0.001). Olaparib was associated with fewer deaths than placebo (59 and 86, respectively) (hazard ratio, 0.68; 99% CI, 0.44 to 1.05; P=0.02); however, the between-group difference was not significant at an interim-analysis boundary of a P value of less than 0.01. Safety data were consistent with known side effects of olaparib, with no excess serious adverse events or adverse events of special interest. CONCLUSIONS Among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than was placebo. Olaparib had limited effects on global patient-reported quality of life.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Tutt, Andrew N. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Garber, Judy E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kaufman, BellaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Viale, GiuseppeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fumagalli, DeboraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rastogi, PriyaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gelber, Richard D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Azambuja, EvandroUNSPECIFIEDorcid.org/0000-0001-9501-4509UNSPECIFIED
Fielding, AnitraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Balmana, JudithUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Domchek, Susan M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gelmon, Karen A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hollingsworth, Simon J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Korde, Larissa A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Linderholm, BarbroUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bandos, HannaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Senkus, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Suga, Jennifer M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Shao, Z.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pippas, Andrew W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nowecki, ZbigniewUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Huzarski, TomaszUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ganz, Patricia A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lucas, Peter C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baker, NigelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Loibl, SibylleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
McConnell, RobinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Piccart, MartineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmutzler, RitaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Steger, Guenther G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Costantino, Joseph P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arahmani, AmalUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolmark, NormanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
McFadden, EleanorUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Karantza, VassilikiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lakhani, Sunil R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yothers, GregUNSPECIFIEDorcid.org/0000-0002-7965-7333UNSPECIFIED
Campbell, ChristineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Geyer, Charles E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-607853
DOI: 10.1056/NEJMoa2105215
Journal or Publication Title: N. Engl. J. Med.
Volume: 384
Number: 25
Page Range: S. 2394 - 2406
Date: 2021
Publisher: MASSACHUSETTS MEDICAL SOC
Place of Publication: WALTHAM
ISSN: 1533-4406
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
DNA-REPAIR DEFECT; MUTANT-CELLS; MUTATION; SURVIVAL; PATHOLOGY; OVARIAN; TUMORSMultiple languages
Medicine, General & InternalMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60785

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item